Verona Pharma is at an exciting stage of its development with data from the final part of its Phase I/II trial of RPL554 (multiple ascending dose trial in COPD patients) due in the coming weeks. This morning’s interim results highlight the significant potential of RPL554 and build on the encouraging early indications from its Phase I/II trial. We remain upbeat about Verona’s future prospects and look forward to the imminent data which represents a significant value inflection point.
